# Giulia Ramazzotti

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2243417/publications.pdf

Version: 2024-02-01

| | | | |
|---|---|---|---|
| 60<br>papers | 1,580<br>citations | 236612<br>25<br>h-index | 329751<br>37<br>g-index |
| 60<br>all docs | 60<br>docs citations | 60<br>times ranked | 1915<br>citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Role of PLCÎ³1 in the modulation of cell migration and cell invasion in glioblastoma. Advances in Biological Regulation, 2022, 83, 100838. | 1.4 | 5 |
| 2 | The wide and growing range of lamin B-related diseases: from laminopathies to cancer. Cellular and Molecular Life Sciences, 2022, 79, 126. | 2.4 | 29 |
| 3 | Roles of PI3K/AKT/mTOR Axis in Arteriovenous Fistula. Biomolecules, 2022, 12, 350. | 1.8 | 2 |
| 4 | Impact of phospholipase C Î²1 in glioblastoma: a study on the main mechanisms of tumor aggressiveness. Cellular and Molecular Life Sciences, 2022, 79, 195. | 2.4 | 12 |
| 5 | Cell signaling pathways in autosomal-dominant leukodystrophyÂ(ADLD): the intriguing role of the astrocytes. Cellular and Molecular Life Sciences, 2021, 78, 2781-2795. | 2.4 | 6 |
| 6 | Lamin B1 Accumulationâ€™s Effects on Autosomal Dominant Leukodystrophy (ADLD): Induction of Reactivity in the Astrocytes. Cells, 2021, 10, 2566. | 1.8 | 3 |
| 7 | Location-dependent role of phospholipase C signaling in the brain: Physiology and pathology. Advances in Biological Regulation, 2021, 79, 100771. | 1.4 | 16 |
| 8 | Morpho-functional alterations in autosomal-dominant leukodystrophy (ADLD): The intriguing role of the astrocytes. Journal of the Neurological Sciences, 2021, 429, 118207. | 0.3 | 0 |
| 9 | Recent advances in MDS mutation landscape: Splicing and signalling. Advances in Biological Regulation, 2020, 75, 100673. | 1.4 | 7 |
| 10 | Abilities of Î²-Estradiol to interact with chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals and alter the proliferation of pancreatic cancer cells. Advances in Biological Regulation, 2020, 75, 100672. | 1.4 | 9 |
| 11 | Subcellular Localization Relevance and Cancer-Associated Mechanisms of Diacylglycerol Kinases. International Journal of Molecular Sciences, 2020, 21, 5297. | 1.8 | 14 |
| 12 | Cancer therapy and treatments during COVID-19 era. Advances in Biological Regulation, 2020, 77, 100739. | 1.4 | 30 |
| 13 | Nuclear Inositides and Inositide-Dependent Signaling Pathways in Myelodysplastic Syndromes. Cells, 2020, 9, 697. | 1.8 | 11 |
| 14 | Lamin A and Prelamin A Counteract Migration of Osteosarcoma Cells. Cells, 2020, 9, 774. | 1.8 | 14 |
| 15 | Phosphoinositide-Dependent Signaling in Cancer: A Focus on Phospholipase C Isozymes. International Journal of Molecular Sciences, 2020, 21, 2581. | 1.8 | 47 |
| 16 | Phosphoinositide 3 Kinase Signaling in Human Stem Cells from Reprogramming to Differentiation: A Tale in Cytoplasmic and Nuclear Compartments. International Journal of Molecular Sciences, 2019, 20, 2026. | 1.8 | 24 |
| 17 | Abilities of berberine and chemically modified berberines to interact with metformin and inhibit proliferation of pancreatic cancer cells. Advances in Biological Regulation, 2019, 73, 100633. | 1.4 | 25 |
| 18 | Inositide-Dependent Nuclear Signalling in Health and Disease. Handbook of Experimental Pharmacology, 2019, 259, 291-308. | 0.9 | 5 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Phospholipase C-Î²1 interacts with cyclin E in adipose- derived stem cells osteogenic differentiation. Advances in Biological Regulation, 2019, 71, 1-9. | 1.4 | 17 |
| 20 | Therapeutic potential of nvpâ€bkm120 in human osteosarcomas cells. Journal of Cellular Physiology, 2019, 234, 10907-10917. | 2.0 | 16 |
| 21 | Nuclear phospholipase C isoenzyme imbalance leads to pathologies in brain, hematologic, neuromuscular, and fertility disorders. Journal of Lipid Research, 2019, 60, 312-317. | 2.0 | 25 |
| 22 | Nuclear inositide signaling and cell cycle. Advances in Biological Regulation, 2018, 67, 1-6. | 1.4 | 30 |
| 23 | Roles of p53, NF-ÎºB and the androgen receptor in controlling NGAL expression in prostate cancer cell lines. Advances in Biological Regulation, 2018, 69, 43-62. | 1.4 | 21 |
| 24 | Nuclear Inositide Signaling Via Phospholipase C. Journal of Cellular Biochemistry, 2017, 118, 1969-1978. | 1.2 | 28 |
| 25 | PLC-Î²1 and cell differentiation: An insight into myogenesis and osteogenesis. Advances in Biological Regulation, 2017, 63, 1-5. | 1.4 | 34 |
| 26 | MiRNA-210: A Current Overview. Anticancer Research, 2017, 37, 6511-6521. | 0.5 | 159 |
| 27 | BMPâ€2 Induced Expression of PLCÎ²1 That is a Positive Regulator of Osteoblast Differentiation. Journal of Cellular Physiology, 2016, 231, 623-629. | 2.0 | 26 |
| 28 | Nuclear translocation of PKCÎ± isoenzyme is involved in neurogenic commitment of human neural crest-derived periodontal ligament stem cells. Cellular Signalling, 2016, 28, 1631-1641. | 1.7 | 40 |
| 29 | Nuclear Phosphatidylinositol Signaling: Focus on Phosphatidylinositol Phosphate Kinases and Phospholipases C. Journal of Cellular Physiology, 2016, 231, 1645-1655. | 2.0 | 48 |
| 30 | Modulation of nuclear PI-PLCbeta1 during cell differentiation. Advances in Biological Regulation, 2016, 60, 1-5. | 1.4 | 25 |
| 31 | IPMK and Î²-catenin mediate PLC-Î²1-dependent signaling in myogenic differentiation. Oncotarget, 2016, 7, 84118-84127. | 0.8 | 7 |
| 32 | An increased expression of PI-PLCÎ²1 is associated with myeloid differentiation and a longer response to azacitidine in myelodysplastic syndromes. Journal of Leukocyte Biology, 2015, 98, 769-780. | 1.5 | 26 |
| 33 | PLC-beta 1 regulates the expression of miR-210 during mithramycin-mediated erythroid differentiation in K562 cells. Oncotarget, 2014, 5, 4222-4231. | 0.8 | 19 |
| 34 | A novel DAG-dependent mechanism links PKCa and Cyclin B1 regulating cell cycle progression. Oncotarget, 2014, 5, 11526-11540. | 0.8 | 17 |
| 35 | Nuclear phospholipase C Î²1 signaling, epigenetics and treatments in MDS. Advances in Biological Regulation, 2013, 53, 2-7. | 1.4 | 32 |
| 36 | Nuclear PLCs affect insulin secretion by targeting PPARÎ³ in pancreatic Î² cells. FASEB Journal, 2012, 26, 203-210. | 0.2 | 27 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Nuclear PI-PLCÎ²1 and Myelodysplastic Syndromes: Genetics and Epigenetics. Current Pharmaceutical Design, 2012, 18, 1751-1754. | 0.9 | 9 |
| 38 | Revisiting nuclear phospholipase C signalling in MDS. Advances in Biological Regulation, 2012, 52, 2-6. | 1.4 | 20 |
| 39 | Nuclear Phosphoinositides: Location, Regulation and Function. Sub-Cellular Biochemistry, 2012, 59, 335-361. | 1.0 | 34 |
| 40 | Nuclear PI-PLC Î²1 and Myelodysplastic Syndromes: From Bench to Clinics. Current Topics in Microbiology and Immunology, 2012, 362, 235-245. | 0.7 | 9 |
| 41 | Physiology and pathology of nuclear phospholipase C Î²1. Advances in Enzyme Regulation, 2011, 51, 2-12. | 2.9 | 16 |
| 42 | Synergistic induction of PI-PLCÎ²1 signaling by azacitidine and valproic acid in high-risk myelodysplastic syndromes. Leukemia, 2011, 25, 271-280. | 3.3 | 36 |
| 43 | The physiology and pathology of inositide signaling in the nucleus. Journal of Cellular Physiology, 2011, 226, 14-20. | 2.0 | 31 |
| 44 | Targeting the Phosphatidylinositol 3-Kinase/Akt/Mammalian Target of Rapamycin Signaling Network in Cancer Stem Cells. Current Medicinal Chemistry, 2011, 18, 2715-2726. | 1.2 | 109 |
| 45 | Nuclear Phospholipase C in Biological Control and Cancer. Critical Reviews in Eukaryotic Gene Expression, 2011, 21, 291-301. | 0.4 | 15 |
| 46 | Inositide signaling in the nucleus: From physiology to pathology. Advances in Enzyme Regulation, 2010, 50, 2-11. | 2.9 | 17 |
| 47 | A role for PKCÎµ during C2C12 myogenic differentiation. Cellular Signalling, 2010, 22, 629-635. | 1.7 | 14 |
| 48 | Nuclear inositide signaling in myelodysplastic syndromes. Journal of Cellular Biochemistry, 2010, 109, 1065-1071. | 1.2 | 25 |
| 49 | eEF1A Phosphorylation in the Nucleus of Insulin-stimulated C2C12 Myoblasts. Molecular and Cellular Proteomics, 2010, 9, 2719-2728. | 2.5 | 26 |
| 50 | Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 16811-16816. | 3.3 | 98 |
| 51 | Involvement of nuclear PLCÎ²1 in lamin B1 phosphorylation and G 2 /M cell cycle progression. FASEB Journal, 2009, 23, 957-966. | 0.2 | 61 |
| 52 | Nuclear inositides: PI-PLC signaling in cell growth, differentiation and pathology. Advances in Enzyme Regulation, 2009, 49, 2-10. | 2.9 | 42 |
| 53 | Inositide signaling: Nuclear targets and involvement in myelodysplastic syndromes. Advances in Enzyme Regulation, 2008, 48, 2-9. | 2.9 | 8 |
| 54 | Catalytic activity of nuclear PLC-Î²1 is required for its signalling function during C2C12 differentiation. Cellular Signalling, 2008, 20, 2013-2021. | 1.7 | 37 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Nuclear phospholipase C beta1 and cellular differentiation. Frontiers in Bioscience - Landmark, 2008, 13, 2452. | 3.0 | 30 |
| 56 | Inositide-Dependent Phospholipase C Signaling Mimics Insulin in Skeletal Muscle Differentiation by Affecting Specific Regions of the Cyclin D3 Promoter. Endocrinology, 2007, 148, 1108-1117. | 1.4 | 53 |
| 57 | Role of nuclear PLC and PI3K signaling in the development of cancer. Future Lipidology, 2007, 2, 303-311. | 0.5 | 2 |
| 58 | Real-time PCR as a tool for quantitative analysis of PI-PLCÎ²1 gene expression in myelodysplastic syndrome. International Journal of Molecular Medicine, 2006, 18, 267. | 1.8 | 5 |
| 59 | Real-time PCR as a tool for quantitative analysis of PI-PLCbeta1 gene expression in myelodysplastic syndrome. International Journal of Molecular Medicine, 2006, 18, 267-71. | 1.8 | 24 |
| 60 | Genotype of inflammatory cytokines in limbal stem cell graft in Italian patients. Biochemical and Biophysical Research Communications, 2005, 332, 95-100. | 1.0 | 3 |